[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AP2007004004A0 - Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors - Google Patents

Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors

Info

Publication number
AP2007004004A0
AP2007004004A0 AP2007004004A AP2007004004A AP2007004004A0 AP 2007004004 A0 AP2007004004 A0 AP 2007004004A0 AP 2007004004 A AP2007004004 A AP 2007004004A AP 2007004004 A AP2007004004 A AP 2007004004A AP 2007004004 A0 AP2007004004 A0 AP 2007004004A0
Authority
AP
ARIPO
Prior art keywords
compoundsas
heteroaromatic
phosphodiesterase inhibitors
pyrrolidyl
derivatives
Prior art date
Application number
AP2007004004A
Other languages
English (en)
Inventor
Thomas Allen Chappie
Michael John Humphrey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2007004004(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2007004004A0 publication Critical patent/AP2007004004A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2007004004A 2004-12-31 2005-12-19 Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors AP2007004004A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64040504P 2004-12-31 2004-12-31
PCT/IB2005/003989 WO2006070284A1 (en) 2004-12-31 2005-12-19 Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
AP2007004004A0 true AP2007004004A0 (en) 2007-06-30

Family

ID=36046318

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004004A AP2007004004A0 (en) 2004-12-31 2005-12-19 Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors

Country Status (23)

Country Link
US (1) US20060183763A1 (es)
EP (1) EP1838702A1 (es)
JP (1) JP2008526726A (es)
KR (1) KR20070086841A (es)
CN (1) CN101087778A (es)
AP (1) AP2007004004A0 (es)
AR (1) AR055298A1 (es)
AU (1) AU2005321015A1 (es)
BR (1) BRPI0519760A2 (es)
CA (1) CA2594251A1 (es)
CR (1) CR9135A (es)
EA (1) EA200701118A1 (es)
GT (1) GT200500367A (es)
IL (1) IL183188A0 (es)
MA (1) MA29119B1 (es)
MX (1) MX2007006301A (es)
NL (1) NL1030819C2 (es)
NO (1) NO20073958L (es)
PE (1) PE20060775A1 (es)
TN (1) TNSN07248A1 (es)
TW (1) TW200637851A (es)
UY (1) UY29317A1 (es)
WO (1) WO2006070284A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531709A (ja) * 2005-03-01 2008-08-14 ワイス シンノリン化合物および肝臓ｘ受容体調節物質としてのそれらの使用
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
BRPI0707223A2 (pt) * 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
AU2007217750A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
JP2009527562A (ja) * 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
AU2007221049A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
EP1996574A1 (en) * 2006-03-08 2008-12-03 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
MX2009012390A (es) * 2007-05-17 2010-06-23 Helperby Therapeutics Ltd Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes.
UA102693C2 (ru) * 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI396689B (zh) * 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
EP2620428B1 (en) * 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
EP2640395A4 (en) * 2010-11-08 2014-01-22 Omeros Corp TREATMENT OF DISEASES ASSOCIATED WITH SEARCH AND PULSE CONTROL BY PDE7 INHIBITORS
RU2013142364A (ru) 2011-02-18 2015-03-27 Аллерган, Инк. Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а)
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
EP2846805B1 (en) * 2012-05-07 2018-11-21 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
BR112015000784A8 (pt) 2012-07-13 2018-04-03 Wave Life Sciences Japan Grupo auxiliar assimétrico
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
ITVI20130032A1 (it) * 2013-02-14 2014-08-15 F I S Fabbrica Italiana Sint I S P A Procedimento per la preparazione di n-boc-pirrolidinone
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015107425A2 (en) 2014-01-16 2015-07-23 Wave Life Sciences Pte. Ltd. Chiral design
TW201611834A (en) * 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
EA032579B1 (ru) * 2014-04-04 2019-06-28 Х. Лундбекк А/С Галогенированные хиназолин-тгф-амины в качестве ингибиторов pde1
WO2016116900A1 (en) * 2015-01-23 2016-07-28 Gvk Biosciences Private Limited Inhibitors of trka kinase
WO2018013676A1 (en) 2016-07-14 2018-01-18 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN106632089B (zh) * 2016-11-04 2019-06-18 中山大学 一类喹唑啉类化合物及其制备方法与应用
AU2018393409A1 (en) * 2017-12-26 2020-08-13 Mediconns (Shanghai) Biopharmaceutical Co., Ltd Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
IL301038A (en) 2020-09-09 2023-05-01 Crinetics Pharmaceuticals Inc Somatostatin modulator formulations
CN115417802A (zh) * 2021-05-16 2022-12-02 上海鼎雅药物化学科技有限公司 乌帕替尼及其中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577432A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
JP3919272B2 (ja) * 1996-12-18 2007-05-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナゾリン系化合物
PT1107965E (pt) * 1998-08-25 2004-10-29 Ortho Mcneil Pharm Inc Eteres e tioeteres de piridilo como ligantes para receptores de acetilcolina nicotinica e as suas aplicacoes terapeuticas
US20020151712A1 (en) * 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
BR0209957A (pt) * 2001-05-21 2004-03-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
EP1638939A2 (en) * 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1755611A1 (en) * 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions

Also Published As

Publication number Publication date
NO20073958L (no) 2007-09-27
UY29317A1 (es) 2006-07-31
NL1030819A1 (nl) 2006-07-03
EA200701118A1 (ru) 2007-12-28
BRPI0519760A2 (pt) 2009-03-10
TW200637851A (en) 2006-11-01
CA2594251A1 (en) 2006-07-06
CN101087778A (zh) 2007-12-12
AU2005321015A1 (en) 2006-07-06
WO2006070284A1 (en) 2006-07-06
CR9135A (es) 2007-08-14
US20060183763A1 (en) 2006-08-17
NL1030819C2 (nl) 2007-01-04
GT200500367A (es) 2006-08-16
MA29119B1 (fr) 2007-12-03
AR055298A1 (es) 2007-08-15
IL183188A0 (en) 2007-08-19
EP1838702A1 (en) 2007-10-03
PE20060775A1 (es) 2006-09-01
MX2007006301A (es) 2007-06-15
KR20070086841A (ko) 2007-08-27
TNSN07248A1 (fr) 2008-11-21
JP2008526726A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
AP2007004004A0 (en) Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
PT1802579E (pt) Derivados da 3-arilaminopiridina
HK1104286A1 (en) Pyrimidine urea derivatives as kinase inhibitors
HK1092458A1 (en) Quinoline derivatives as phosphodiesterase inhibitors
AU2003251559A8 (en) Heterocyclic inhibitors of kinases
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
HK1107348A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
ZA200701942B (en) Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL178968A0 (en) Novel pyridazinone derivatives as inhibitors of cdk2
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
PL1763517T3 (pl) Pochodne pirymidyny jako inhibitory 11BETA-HSD1
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
ZA200609510B (en) Pyrimidine urea derivatives as kinase inhibitors